• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Cosmetics
  • Measures for Cosmetics Adverse Reaction Monitoring Coming Into Effect on October 1, 2022

Measures for Cosmetics Adverse Reaction Monitoring Coming Into Effect on October 1, 2022

Measures for Cosmetics Adverse Reaction
Friday, 25 March 2022 / Published in Cosmetics, News, NMPA Registration in China

Measures for Cosmetics Adverse Reaction Monitoring Coming Into Effect on October 1, 2022

Measures for cosmetics adverse reaction monitoring was issued (No.16-2022) on February 21, 2022 by the NMPA (National Medical Products Administration) as the finalized regulatory measure for monitoring the adverse reactions of cosmetics in China. The measure was written in accordance to the new Cosmetics Administration and Supervision Regulations (CSAR), and will come into effect on October 1, 2022.

Highlights – Measures for cosmetics adverse reaction monitoring

  • The regulatory document consists of 7 chapters and 47 articles covering general provisions, duties and obligations for adverse reaction reporting, adverse reaction analysis and evaluation, adverse reaction investigation, etc.
  • Overseas registrants and filers should establish a system with their domestic responsible person for collecting and carrying out evaluation, reports and investigations on adverse reactions.
  • Adverse reactions are classified into three levels: General, Serious, and Great Impact to the Community. There are corresponding regulatory measures to be carried out for each different levels of classification.
  • Adverse reaction monitoring plays an important role in post-market risk warning, and this regulatory measure aims to enhance the level of risk prevention and control effectively.

By Jeff Jiang. Contact Cisema if you would like to learn more.

Tagged under: Adverse Events, cosmetics

What you can read next

ICH E8 (R1)
ICH E8 (R1) General Considerations for Clinical Studies have been approved in China
Advertisement of Life Science Products
CCC electronics self-inspection pilot work
CCC electronics self-inspection pilot work launched by the CNCA

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Clinical trials of sodium hyaluronate complex solution

    Clinical trials of sodium hyaluronate complex solution – draft guidelines issued

    Clinical trials of sodium hyaluronate complex s...
  • China registration of ophthalmic optical measurement devices

    China registration of ophthalmic optical measurement devices – Technical review guidelines issued

    China registration of ophthalmic optical measur...
  • Pre-communication for Hainan medical device clinical RWD

    Pre-communication for Hainan medical device clinical RWD application – Trial measures implemented

    Pre-communication for Hainan medical device cli...
  • Registration platform for cosmetic raw materials safety information

    Registration platform for cosmetic raw materials safety information – Draft guidelines issued

    The registration platform for cosmetic raw mate...
  • Technical guidelines for reporting cosmetics formulas

    Technical guidelines for reporting cosmetics formulas – draft issued

    Technical guidelines for reporting cosmetics fo...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP